May 18, 2015 — A risk assessment algorithm combining clinical risk factors and platelet function test results may help ...
Antiplatelet and Anticoagulation Therapies
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.
May 18, 2015
May 18, 2015 — Patients with a high-risk paclitaxel drug-eluting stent given the shorter-acting antiplatelet drug cilost ...
May 18, 2015
May 15, 2015 — Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing percutaneo ...
May 15, 2015May 14, 2015 — A new study reports that antiplatelet drug ticagrelor (Brilinta) works faster and is more effective in bl ...
May 14, 2015
May 6, 2015 — People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent ...
May 06, 2015One life-threatening complication of lung cancer surgery is the formation of blood clots in the lungs (also called ...
May 01, 2015
April 30, 2015 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new ...
April 30, 2015
April 29, 2015 — The Medicines Company announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and ...
April 29, 2015March 30, 2015 — The Medicines Company announced that the European Commission has granted marketing authorization for ...
March 30, 2015
March 30, 2015 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved a new ...
March 30, 2015March 25, 2015 — Adding the antiplatelet drug ticagrelor (Brilinta) to aspirin as long-term therapy after a heart attack ...
March 26, 2015March 15, 2015 — A novel therapy that would allow doctors to turn the body’s blood clotting ability off and on in a more ...
March 25, 2015March 24, 2015 — Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug ...
March 24, 2015
March 19, 2015 — Data from a meta-analysis published recently in The Lancet found that extended-duration dual ...
March 19, 2015
March 16, 2015 — Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) approval for the Watchman ...
March 16, 2015© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now